Last updated on November 2018

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acquired Hemophilia A
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Must be 18 years;
  2. Understand and voluntarily sign an ICD prior to any study related assessments/procedures are conducted;
  3. Diagnosis of acquired hemophilia A
  4. acute bleeding episodes(once).

Exclusion Criteria:

  1. Uncontrolled systemic infection;
  2. Allergy to rituximab;
  3. Positive for Lupus anticoagulant;
  4. Life expectancy < 3 months;
  5. Pregnant and breastfeeding women;
  6. Neuropathy>Grade 1;
  7. Positive for Hepatitis B surface antigen or hepatitis C antibody or human immunodeficiency virusHIVantibody;
  8. Patients with poor compliance
  9. Patient who is considered by the investigator not suitable for clinical study.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.